古根海姆资本公司削减了在Vertex制药公司(Vertex Pharmicals)的股份,因为该公司损失了收入,但上季度股票仍猛涨108.2%。 Guggenheim Capital cut its stake in Vertex Pharmaceuticals, which missed earnings, but the stock still surged 108.2% last quarter.

古根海姆资本在第四季度将Vertex制药公司持有的股份减少了3 596股,现在拥有135 695股。 Guggenheim Capital reduced its holdings in Vertex Pharmaceuticals by 3,596 shares in the fourth quarter, now owning 135,695 shares. 开发囊性纤维化治疗的Vertex公司每股收益预期不足0.45美元, 净利率为-4.86%. Vertex, which develops cystic fibrosis treatments, missed earnings per share expectations by $0.45, with a net margin of -4.86%. 尽管价格与收益之间的负比为-225.38,分析家预测Vertex将在本年度发布15.63 EPS,第四季度的存货增长了108.2%。 Despite a negative price-to-earnings ratio of -225.38, analysts predict Vertex will post 15.63 EPS for the year, and the stock has seen a 108.2% increase in the fourth quarter.